Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
Complete Title: A Phase 2 study of PHE885, B-Cell Maturation Antigen (BCMA) Directed CAR-T Cells in Adult Participants with Relapsed and Refractory Multiple Myeloma.
Trial Phase: II
Investigator: Rahul Banerjee
This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple myeloma
Keywords:
- Multiple Myeloma (MM)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
Pediatric
II
Rahul Banerjee
RG1122615
NCT05172596
A Phase 2 study of PHE885, B-Cell Maturation Antigen (BCMA) Directed CAR-T Cells in Adult Participants with Relapsed and Refractory Multiple Myeloma.
Multiple Myeloma (MM)